It has been noticed that the presence before treatment of high percentage of PD-1+ CD8+ TILs in NSCLC treated with durvalumab had better overall response rate (ORR) (37% vs. 7%), better OS (24.3 vs. 6.5m), and also better progression-free survival (PFS) (7.3 vs. 2.6m) compared to those patients with a low percentage of PD-1+ CD8+ TILs [18]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.